INS and type 2 diabetes mellitus: One month after twice a week recombinant IL-22 treatment in Mtb-infected T2DM mice, compared with PBS-treated Mtb-infected T2DM mice, serum insulin levels were significantly decreased (2.57 ± 0.17 vs. 1.55 ± 0.78, p<0.05, Fig 3D), and serum free fatty acids (460.9 ± 93.96 vs. 351.1 ± 34.87, p<0.05, Fig 3E) and triglycerides (174.7 ± 51.04 vs. 107.6 ± 4.98, p<0.05, Fig 3F) were marginally reduced.